dll3-car-nk cells
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2022 (NCT05507593)
Timeline
Indications
Mechanism of action
- Delta-like protein 3Immunity, passive
immunity, passive - DLL3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07172412 | Phase 2 | Nov 30, 2025 | Tianjin Medical University |
| NCT07193966 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2025 | Shenzhen Geno-Immune Medical Institute |
| NCT05507593 | Phase 1 | Sep 1, 2022 | Tianjin Medical University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1